Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in NNOX.

← Back to Free Index

NNOX

Analysis as of: 2026-09-14

Nano-X Imaging Ltd.

Nanox develops low-cost digital tomosynthesis imaging systems and sells related radiology, AI, cloud, marketplace, and health IT services to healthcare providers.

ai cloud healthcare medical devices software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Financing Gate in Front of a Real Platform

The business now has clearer proof points, including first scans, reimbursement, and more channels, but the balance sheet still decides whether those proofs compound. The opportunity is large because the market is still valuing survival more than successful activation.

Analysis

Thesis

Nanox is a financing-gated option on turning a tiny base of cleared imaging deployments into recurring scan, radiology, workflow, and AI revenue; if it proves activation and reimbursement before dilution overwhelms the equity, the stock can rerate sharply from distress because today it is valued more like a funding problem than a functioning imaging utility.

Last Economy Alignment

Moderately positive. Cheaper AI should raise the value of Nanox’s scan-to-report bundle, but the company does not own a core AI bottleneck; funding, activation speed, and regulated workflow adoption still decide whether it captures that value.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

13.4x (from 5 most recent analyses)

Reasoning

This is a survival-to-scale rerating story. If Nanox converts distributor signatures into activated, reimbursed sites and shifts mix toward recurring radiology, workflow, and AI contracts, the market can stop pricing it mainly as a financing problem. I cap the upside below premium healthcare software because hardware support, clinical labor, and regulation keep revenue quality mixed and dilution risk real.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

This is a sequence-risk equity. Nanox first has to secure runway, then activate sites, then prove that recurring scan, workflow, and radiology revenue can outrun hardware drag and dilution. The company has real regulatory assets and a credible bundled model, but if cash or activations break, the AI upside will not matter.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

September 9 results added the first NIN patient scans and initial insurer reimbursement, which modestly strengthens commercialization proof.
September 9 disclosures also reaffirmed that cash at June 30 was not enough for 12 months, so survival risk remains the governing variable.
A new New England distributor was added on September 4, expanding the U.S. channel without yet proving activation velocity.
A Costa Rica distributor was announced on September 10, but that market starts with a six-month POC registration gate, so signing does not equal revenue.
The September 17 shareholder vote on authorized shares moved into the immediate catalyst window and directly affects financing flexibility.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.33

They own a cleared scanner plus the cloud and radiology workflow around it, so AI can make the whole service bundle more useful once sites are live. The problem is that bigger vendors have stronger channels today, and weak funding can stop Nanox’s flywheel before it starts.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$4.33

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research